Google
Trusted Resources: News & Events
Latest announcements and gatherings
MARAC Statement: Penicillin Shortage
Penicillin VK solution is suffering from intermittent supply shortages. This can affect children with sickle cell disease. Penicillin VK in liquid form is prescribed for babies and young children with sickle cell disease who are unable to swallow pills as standard care, twice a day, starting as early as 6-8 weeks of age. Children less than 3 years of age should receive oral penicillin 125 mg twice daily, and the dose should be increased to 250 mg twice daily for children older than 3 years.
+myBinderRelated Content
-
Cerebral haemorrhagic risk in children with sickle-cell diseaseAIM: To address risk of first or recurre...
-
Sickle Cell in Focus Conference 2018After an exciting event in Kingston, Jam...
-
Acute Chest Syndrome – A HRSA EMBRACE Projecthttps://www.youtube.com/watch?v=wRzTQfhG...
-
An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomesOBJECTIVE: To identify characteristics ...
-
FDA Advisory Committee Recommends Approval of Endari™ from Emmaus Life Sciences for the Treatment of Sickle Cell D...Emmaus Life Sciences Inc. announced toda...
-
Courtney Fitzhugh, MDCourtney Fitzhugh received her B.S. magn...
-
Yoga for Chronic Pain – US Pain FoundationDuring this interactive live webinar, in...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.